Drug Trial Radar · NCT01223378
Study Comparing the Safety and Efficacy of BOL-303259-X to Latanoprost in Subjects With Glaucoma or Ocular Hypertension
Last checked: Nov 20, 2026Latest source record: Jul 24, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
413
Actual
Start
Dec 13, 2010
Primary completion
Dec 20, 2011
Study completion Jun 22, 2012
Sponsor
- Lead sponsor
- Bausch & Lomb IncorporatedIndustry
- Sponsor type
- Industry
- First posted
- Oct 19, 2010
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (investigator)
- Primary purpose
- Screening
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of this clinical investigation is to determine the most effective drug concentration(s) of BOL-303259-X in the reduction of IOP in order to support further clinical development of an appropriate dose with regard to efficacy, and ocular and systemic safety.
Conditions
- Intraocular Pressure
Interventions
BOL-303259-XDrug
ophthalmic solution, various concentrations, once daily (QD) 28 days
LatanoprostDrug
0.005% ophthalmic solution, QD 28 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Mean Diurnal IOP at Visit 6 (Day 28)Time frame: Baseline and Visit 6 (Day 28)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Bausch & Lomb, Inc
Rochester, New York
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.